INTRODUCTION
Vascular tumors are endothelial cell (EC) neoplasms with a wide spectrum of clinical presentations, ranging from benign infantile hemangiomas in children to low-grade malignant hemangioendotheliomas and highly aggressive angiosarcomas in adults. To date, the molecular pathogenesis of vascular tumors is poorly understood and current therapies, particularly those for malignant vascular tumors, do not significantly improve patient outcome (1).
Akt is a major signaling pathway activated by vascular endothelial growth factor (VEGF) that regulates EC survival (2) . In infantile hemangioma (IH), hemangioma-derived endothelial cells (hemeEC) have constitutively active VEGF receptor-2 signaling with high phosphorylation levels of ERK1/2 and Akt (3). Human angiosarcoma (AS) expresses VEGF-A and the VEGF receptors (4) . We have shown increased phosphorylation of Akt and 4E-BP1 in AS (5) .
Hyperactivation of PI3-kinase results in hemangiosarcoma formation in chicken chorioallantoic membrane (6) . Akt1, Akt2 and Akt3 are isoforms that have shared as well as distinct functions in cancer cells. Both Akt1 and Akt2 promote cancer cell survival and growth. However, in breast and ovarian cancer, Akt1 decreases cell motility and metastasis and blocks epithelial-tomesenchymal phenotype, whereas Akt2 enhances these processes (7) (8) (9) . Akt3 is preferentially required for the growth of triple-negative breast cancer (10) , and a gene fusion of Akt3 with MAGI3 leads to constitutive Akt3 activation and is enriched in these tumors (11) . Interestingly, there is some evidence suggesting that Akt3 exerts inhibitory effects in cancer. N-Cadherin promotes breast cancer metastasis by inhibiting Akt3, and Akt3 has been shown to inhibit lung tumor growth in mice (12) (13) (14) . Studies of animal models of breast cancer with simultaneous deletion or overexpression of Akt1, Akt2 and Akt3 lend further support to Akt isoform-specific roles in cancer (8, 9) .
Mammalian target of rapamycin (mTOR) complex-1 (mTORC1) and complex-2 (mTORC2) are composed of multiple subunits, including mTOR and Raptor (in mTORC1), and mTOR and Rictor (in mTORC2) (15, 16) . Akt activates mTORC1, which phosphorylates the translational regulators 4E-BP1 and p70 S6-Kinase (S6K). S6K in turn activates S6 ribosomal protein (S6) (17, 18) . mTORC2 directly activates Akt by phosphorylating it at serine 473, thereby exerting feedback regulation on the Akt signaling pathway (15) . The S6K pathway is important in protein synthesis and cell growth, and acts as a regulator of actin cytoskeleton dynamics in cell migration (19, 20) .
In this study, we showed that endothelial Akt1 drives vascular tumor growth.
Importantly, we have uncovered the opposing functions of Akt1 and Akt3 in the regulation of tumor growth, which is mediated through S6K, and found a novel negative feedback regulation on Akt3 by S6K. We also demonstrated the clinical utility of a novel S6K inhibitor in the treatment of vascular lesions.
MATERIALS AND METHODS

Animals. Animal studies were conducted in compliance with the Beth Israel Deaconess
Medical Center (BIDMC) Institutional Animal Care and Use Committee guidelines. Double transgenic myristoylated Akt1 mice in mixed FVB genetic background have been previously described (21). C57 Bl/6 Akt3-/-mice were from Argiris Efstratiadis and Morris Birnbaum (22) .
Cell lines and reagents. The use of human tissues was approved by the Institutional Review
Boards at BIDMC and Baylor College of Medicine. Primary human dermal microvascular endothelial cells (EC), infantile hemangioma and mouse EC were isolated as described (21, 23).
ASM.5 cells were from Vera Krump-Konvalinkov and EOMA cells were from ATCC as previously published (23) (24) (25) . Cell line authentication and validation by short tandem repeats was performed. HA-tagged-MyrAkt3 and constitutively active S6K (R3A) have been described (26, 27) . LY2584702 (Eli Lilly, Inc.) was prepared in 0.25% Tween-80 and 0.05% antifoam, and administered orally to mice (12.5 mg/kg twice daily). All antibodies used were from Cell Signaling Technologies, except for antibodies to smooth muscle actin, β-actin and -tubulin (Sigma), CD31 (BD Biosciences) and glucose transporter-1 (Dr. Morris Birnbaum).
Mouse hemangioma skin graft model. Ten-mm circular pieces of flank skin from donor myrAkt1 mice were grafted onto the back of recipient mice with absorbable Vicryl sutures (Ethicon). Recipient animals were maintained on 1.5 mg/ml tetracycline in the drinking water as described (21) to turn off myrAkt1 while the grafts were left to heal for 2 weeks. After this time, half of the recipients continued to receive tetracycline for 4 weeks, while the other half was taken off tetracycline to turn on myrAkt1 expression. Methods. Lentivirus packaging and qPCR were performed as described (23) .
Statistical analysis. Data were presented as mean ± SD. The difference between multiple experimental groups was assessed by one-way ANOVA, and the difference between multiple experimental groups at different time points (two independent variables) was assessed by twoway ANOVA using GraphPad Prism.
Other standard reagents and methods are provided in Supplementary Materials and Methods. 
RESULTS
Akt is activated in human vascular tumors. Clinical specimens of 17 benign infantile hemangioma (IH), 6 kaposiform hemangioendothelioma (KHE), 16 Kaposi's sarcoma (KS) and 9 angiosarcoma (AS) were stained for phosphorylated Akt Serine 473 (pAkt S473). All of the tumors expressed increased pAkt levels compared to adjacent normal blood vessels in the same tissue sections ( Figure 1A ). We also compared the levels of pAkt in these tumors with blood vessels in 20 normal skin specimens as the normal counterpart of neoplastic vessels.
The percent positively stained tumor cells (stain reactivity) and the stain intensity per group were calculated. Higher pAkt stain reactivity was seen in vascular tumors than in normal skin (73.3±2.1% in normal skin vs. 92.3±1.3%* in IH, 95.5±1.2%* in KHE, 92.3±1.3%* in KS and 89.7±1.9%* in AS; *P<0.0001) ( Figure 1B) . To evaluate the stain intensity, the staining was scored using a 3-tier system (1, low; 2, moderate; and 3, high) by two pathologists and the average score was graphed. Representative pictures of low and high stain intensity are shown (Supplementary Figure S1) . Significantly higher pAkt stain intensity was seen in tumors (1.6 ± 0.1 in normal skin vs. 2.1 ± 0.2* in IH, 2.2 ± 0.3* in KHE, 2.5 ± 0.2* in KS and 3.0 ± 0.03* in AS; *P<0.01) ( Figure 1C and Supplementary Figure S1 ). These results showed increased Akt activation across different types of human vascular tumors.
To determine whether Akt is hyperactivated in neoplastic EC, we focused on IH, which is a common soft tissue tumor of infancy and fresh tissues are available for studies. We purified hemangioma-derived endothelial cells (hemeEC) from IH using CD31-magnetic bead isolation and stained for endothelial markers (Supplementary Figure S2A) . HemeEC showed a 1.9-fold increase in pAkt as compared with normal human dermal microvascular endothelial cells (HDMEC) by western blot ( Figure 1D ). Consistent with a previous report of constitutive VEGFR- samples. Interestingly, PTEN levels were also reduced in some hemangiomas. These findings showed increased Akt activation in IH, which is associated with decreased PTEN and increased VEGFR-2 activation.
We next examined Akt activation in malignant vascular tumors. We utilized ASM.5 cells isolated from a spontaneous human angiosarcoma (24) , and EOMA cells derived from a spontaneous mouse hemangioendothelioma (25) . ASM.5 and EOMA cells had increased Akt activation as compared with normal EC (Figures 1E-F Endothelial Akt1 activation induces hemangioma formation in mice. To determine whether Akt1 activation in EC is sufficient to drive de novo vascular tumor formation, we utilized a double transgenic mouse model that expresses tetracycline-inducible and endothelial cell-specific activated myristoylated Akt1 (myrAkt1) (21). myrAkt1 transgene induction increased Akt1 expression by 3.9-fold, but did not affect Akt2 and Akt3 levels in EC isolated from these mice (Supplementary Figures S3A-B) . myrAkt1 mice have systemic pathological angiogenesis, but they do not develop vascular tumors due to shortened lifespan from systemic edema (21). To study the long-term effects of endothelial Akt1 activation, we developed a skin graft model in which 10-mm circular pieces of skin from myrAkt1 donors (FVB background) were transplanted onto the back skin of immunodeficient nu/nu mice ( Figure 3A ). Recipient animals were maintained on tetracycline to turn off myrAkt1 while the grafts were left to heal for 2 weeks.
After this time, animals were either kept on tetracycline (myrAkt1 expression off) or taken off tetracycline (myrAkt1 on) for 4 weeks. Without myrAkt1 expression, a dermal scar was present but no tumor was seen ( Figure 3B ). However, induction of myrAkt1 resulted in the development of red tumor masses at the graft sites. The tumors measured 0.39 ± 0.14 cm 3 in size and had histologic features consistent with benign hemangiomas ( Figure 3C ). The tumor vessels coexpressed the endothelial marker CD31 and HA-tagged myrAkt1 ( Figure 3D ). Abundant pAkt was seen in tumor vessels, some of which contained a covering of smooth muscle actin (SMA) while many were SMA-deficient. Interestingly, the expression of glucose transporter-1 (Glut-1), a biomarker found uniquely in human IH (29) , was seen in CD31+ vessels. We also performed hemangioma to develop. After 4 weeks, myrAkt1 expression was turned off in half of the animals while myrAkt1 expression continued to be on in the other half. Tumors in animals with sustained myrAkt1 expression continued to grow, but those in animals with myrAkt1 turned off regressed dramatically over the next 3.5 weeks and had few vessels and more fibrofatty tissue ( Figures 3E-F) . Thus, sustained endothelial Akt1 activation is required to maintain the integrity of blood vessels in this vascular tumor model, and supports our previous finding of the "plasticity" of the microvasculature in response to Akt1 signaling (21).
Akt3 expression is reduced in vascular tumors. Immunostains for Akt1, Akt2 and Akt3 in 15
IH and 10 AS samples showed that the levels of Akt1 and Akt2 in these tumors were similar to those present in adjacent normal blood vessels in the same tissue sections ( Figure 4A ). By contrast, Akt3 levels were reduced in tumor tissues. We next compared the levels of Akt isoforms in vascular tumors with the blood vessels in 6 normal human skin specimens ( Figure   4B ). The stain reactivity and stain intensity were calculated as described for pAkt stains in reactivity for Akt3 was lower in IH (88.7 ± 2.3% in normal skin vs. 69.5 ± 8.3%* in IH; *P<0.05), but not in AS (88.7 ± 2.3% in normal skin vs. 87.8 ± 2.0% in AS; P-value = not significant).
Immunoblots for Akt3 in ASM.5 and EOMA cells showed that they had significantly lower Akt3 levels than normal EC, which is consistent with the findings in patient tumor tissues (Supplementary Figure S5) . We did not observe a significant change in Akt3 in hemeEC. To examine the phosphorylation status of Akt isoforms, ASM.5 cells were immunoprecipitated with antibodies specific for Akt1, Akt2 and Akt3, and immunoblotted for each Akt isoform and phospho-Akt. Akt1 and Akt3 were phosphorylated at both threonine 308 (T308) and S473 residues, sites that are required for full Akt activation ( Figure 4C ). Interestingly, Akt2 did not appear to be phosphorylated in these studies, indicating that only Akt1 and Akt3 are the two active isoforms in these tumor cells. To evaluate the functions of Akt isoforms in vivo, Akt1, Akt2 and Akt3 were knockeddown in EOMA cells using independent shRNA clones for each isoform (Supplementary Figure   S6D ). Cells were then injected subcutaneously in nu/nu mice and tumor size was monitored for 12 days. Loss of Akt1 reduced tumor growth; loss of Akt2 had no effect, whereas loss of Akt3 enhanced tumor growth ( Figure 5F and Supplementary Figure S6E ). These findings demonstrate the opposing roles of Akt1 and Akt3 in vascular tumor growth. We also utilized a small molecule inhibitor of S6K, LY2584702. LY2584702 is highly selective for S6K1 when tested against 83 different kinases and 45 cell surface receptors. In S6K1 enzyme assay, the drug's IC 50 = 2 nM. For pS6 inhibition in cells, the IC 50 = 100 nM (Supplementary Table S1 ). The drug has some activity against the S6K-related kinases MSK2
and RSK at high concentrations (enzyme assay IC 50 = 58-176 nM). LY2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose dependent manner ( Figure 6F ). To examine the role of S6K in vivo, EOMA cells We observed that knockdown of Akt3, but not Akt1, significantly reduced Rictor mRNA ( Figure   7C ). These findings indicate that Akt3 positively regulates Rictor levels, at least in part by modulating Rictor mRNA expression.
To determine whether Rictor affects S6K phosphorylation, we knocked down Rictor and immunoblotted for pS6K and pS6 (mTORC1 activity) and pAkt S473 (mTORC2 activity). Rictor knockdown decreased pAkt levels in both EOMA and ASM.5 cells ( Figure 7D To more definitely demonstrate that the inhibitory effects of Akt3 on S6K is mediated by Rictor, we performed a rescue experiment in which constitutively activated myristoylated Akt3 which the expression of Akt3 is lower in the tumor than in normal brain tissue; however, the remaining Akt3 has kinase activity (36) . This suggests that although the level of endogenous Akt3 is reduced, it still retains the functional capacity as an active kinase. Different Akt isoforms can signal via distinct downstream pathways that may vary depending on the cellular context and subcellular localization (37) . Akt1 and Akt3, but not Akt2 ablation in mice predominantly influences GSK-3 α/β signaling in a mouse lung tumor model (14) . Akt3, but not Akt1, is crucial for the activation of the mTORC1/S6K signaling pathway in the brain, thus reinforcing the differential effects of Akt isoforms on the S6K pathway (22) . We have found that Akt1 and Akt3 exert distinct effects on S6K signaling: Akt1 stimulates, whereas Akt3 inhibits S6K activation. To determine how Akt3 regulates S6K activation, we showed that knockdown of Akt3 leads to reduced Rictor protein levels, which is due at least in part to a reduction of Rictor mRNA expression.
Overexpression of myrAkt3 increases Rictor levels and reduces S6K activation.
Importantly, knockdown of Rictor in cells with myrAkt3 overexpression rescues the effects of myrAkt3 on S6K. Taken together, these findings suggest a potential mechanism by which Akt3 regulates S6K activation through Rictor. We postulate that by regulating Rictor levels, Akt3 can affect the formation of mTOR complexes and the balance of mTORC1 and mTORC2 activities in the cell. Published studies lend support to this hypothesis. The formation of TOR complexes in Caenorhabditis elegans is controlled by semaphorin-plexin signaling, in which semaphorin promotes the formation of TORC1 and inhibits TORC2 by promoting a shift of TOR from Rictor towards Raptor, thereby altering the ratio of TORC1 and TORC2 (38) . Another mechanism of regulation of mTOR complex assembly involves the mTOR inhibitor rapamycin. Rapamycin mainly inhibits mTORC1, but long-term drug treatment can lead to the inhibition of mTORC2, in which rapamycin may sequester mTOR and interfere with the assembly of mTORC2 (39). 
Emerging studies have highlighted the importance of negative feedback loops that normally operate to dampen various types of signaling, and therefore ensure homeostatic regulation of signals in the cell. We have found that S6K exerts negative feedback regulation on Akt3. This is consistent with the known S6K-mediated negative feedback on the PI3 Kinase-Akt pathway (31). The selective feedback effects of S6K on Akt3 may reflect the collective pressure in tumor cells to lower Akt3 levels as a way to counteract the inhibitory effects of active Akt3. 
